Immunovant (IMVT) Rises 14.0% Following $550 Million Equity Raise Backed by Roivant for IMVT-1402 - Is the Bullish Outlook Still Valid?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy ROIV?
Source: Yahoo Finance
Equity Offering Details: Immunovant raised US$550.20 million through a follow-on equity offering, issuing 26.2 million shares at US$21.00 each, primarily to fund the development of its lead candidate IMVT-1402 for Graves’ disease and other autoimmune conditions.
Roivant Sciences' Commitment: Controlling shareholder Roivant Sciences invested approximately US$349.90 million in the offering, which strengthens Immunovant's financial position as it prepares for pivotal clinical trials and a potential product launch.
Shift in Risk Profile: The capital raise alleviates immediate cash flow concerns but shifts the focus to execution risks related to clinical trials and ongoing losses, which exceed US$400 million annually.
Valuation Insights: Analysts suggest Immunovant's share price may be overvalued, with estimates varying widely; some believe the stock could be worth up to 49% more than its current price, highlighting the need for careful evaluation of investment risks and opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.850
Low
22.00
Averages
27.63
High
33.00
Current: 27.850
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Settles for $2.25 Billion with Genevant and Arbutus Over Patent Infringement
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent on a favorable appeal ruling, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting Moderna's accountability in patent infringement cases.
- Patent Licensing Agreement: Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation against Moderna and ensuring compliance for future technology use.
- Significant Market Impact: This settlement not only resolves a long-standing dispute for Moderna but may also affect its competitive position in the COVID-19 vaccine market, especially in light of ongoing litigation with Pfizer/BioNTech.
- Capital Return Plan: Arbutus announces it is evaluating a potential return of capital to shareholders in Q3 2026, which, combined with the upfront payment from the settlement, could enhance investor confidence and improve the company's financial standing.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
Moderna Settles $2.25 Billion Patent Dispute with Genevant and Arbutus
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a successful appeal, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting the importance of intellectual property.
- Technology Licensing Agreement: As part of the settlement, Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation related to its COVID-19 vaccines, ensuring the legality of Moderna's products.
- Acknowledgment of Legal Liability: Moderna agrees to acknowledge infringement on four Genevant/Arbutus patents and consents to a court judgment of no invalidity, which not only reduces future legal risks but also secures the company's ongoing operations in the vaccine market.
- Positive Market Reaction: This settlement is expected to provide significant cash inflow for Roivant, enhancing its capital efficiency and supporting a $500 million share repurchase plan, which will further boost investor confidence and potentially drive stock price appreciation.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
Priovant's Dermatomyositis Drug Receives FDA Priority Review
- FDA Review Progress: Priovant Therapeutics' brepocitinib has received Priority Review from the FDA, with a target action date in Q3 2026, and if approved, it will be the first targeted therapy for dermatomyositis, addressing urgent patient needs.
- Clinical Trial Results: The Phase 3 VALOR study demonstrated significant efficacy of brepocitinib in 241 patients, with the 30 mg dose showing statistically significant improvement in the Myositis Total Improvement Score (TIS) at 52 weeks compared to placebo, indicating its potential to enhance patient quality of life.
- Market Potential: If approved, brepocitinib will provide a new treatment option for dermatomyositis patients who have long relied on high-dose steroids, potentially reducing disease burden and improving quality of life significantly.
- Company Commitment: Priovant CEO Ben Zimmer emphasized the company's commitment to working closely with the FDA to expedite the drug's availability, reflecting a strong dedication to meeting the needs of dermatomyositis patients.
See More
Moderna Settles for $2.25 Billion with Genevant and Arbutus Over Patent Infringement
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent on a favorable appeal ruling, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting Moderna's accountability in patent infringement cases.
- Patent Licensing Agreement: Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation against Moderna and ensuring compliance for future technology use.
- Significant Market Impact: This settlement not only resolves a long-standing dispute for Moderna but may also affect its competitive position in the COVID-19 vaccine market, especially in light of ongoing litigation with Pfizer/BioNTech.
- Capital Return Plan: Arbutus announces it is evaluating a potential return of capital to shareholders in Q3 2026, which, combined with the upfront payment from the settlement, could enhance investor confidence and improve the company's financial standing.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
Moderna Settles $2.25 Billion Patent Dispute with Genevant and Arbutus
- Record Settlement Amount: Moderna will pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a successful appeal, making this the largest disclosed patent settlement in the pharmaceutical industry, highlighting the importance of intellectual property.
- Technology Licensing Agreement: As part of the settlement, Genevant grants Moderna a global non-exclusive license to use LNP delivery technology for SM-102-containing mRNA vaccines, effectively ending all patent infringement litigation related to its COVID-19 vaccines, ensuring the legality of Moderna's products.
- Acknowledgment of Legal Liability: Moderna agrees to acknowledge infringement on four Genevant/Arbutus patents and consents to a court judgment of no invalidity, which not only reduces future legal risks but also secures the company's ongoing operations in the vaccine market.
- Positive Market Reaction: This settlement is expected to provide significant cash inflow for Roivant, enhancing its capital efficiency and supporting a $500 million share repurchase plan, which will further boost investor confidence and potentially drive stock price appreciation.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
Priovant's Dermatomyositis Drug Receives FDA Priority Review
- FDA Review Progress: Priovant Therapeutics' brepocitinib has received Priority Review from the FDA, with a target action date in Q3 2026, and if approved, it will be the first targeted therapy for dermatomyositis, addressing urgent patient needs.
- Clinical Trial Results: The Phase 3 VALOR study demonstrated significant efficacy of brepocitinib in 241 patients, with the 30 mg dose showing statistically significant improvement in the Myositis Total Improvement Score (TIS) at 52 weeks compared to placebo, indicating its potential to enhance patient quality of life.
- Market Potential: If approved, brepocitinib will provide a new treatment option for dermatomyositis patients who have long relied on high-dose steroids, potentially reducing disease burden and improving quality of life significantly.
- Company Commitment: Priovant CEO Ben Zimmer emphasized the company's commitment to working closely with the FDA to expedite the drug's availability, reflecting a strong dedication to meeting the needs of dermatomyositis patients.
See More
